$6.50 1.4%
CTKB Stock Price vs. AI Score
Data gathered: November 27

AI Score



Sign up to see AI score

Brand Score Sign up
Employment Score Sign up
User Growth Score Sign up
Fundamental Score Sign up

AI Stock Analysis - Cytek BioSciences (CTKB)

Analysis generated October 31, 2024. Powered by Chat GPT.

Cytek BioSciences is a pioneering company in the field of cytometry solutions, providing advanced cell analysis technology and services. The company's robust product lines and innovative solutions have helped position it as a key player in this niche market. With a focus on continuous development and partnerships, Cytek BioSciences aims to expand its market share and advance the science of cell analysis to benefit the broader biomedical community.

Read full AI stock Analysis

Stock Alerts - Cytek BioSciences (CTKB)

company logo Cytek BioSciences | November 26
Price is down by -5.4% in the last 24h.
company logo Cytek BioSciences | November 21
Price is up by 5.2% in the last 24h.
company logo Cytek BioSciences | November 20
Employee Rating is down by 2.6% over the last month.
company logo Cytek BioSciences | November 15
Price is down by -5.5% in the last 24h.

About Cytek BioSciences

Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications.


Cytek BioSciences
Price $6.50
Target Price Sign up
Volume 421,010
Market Cap $862M
Year Range $4.69 - $7.4
Dividend Yield 0%
PE Ratio 351.5
Analyst Rating 67% buy
Industry Medical Devices

In the news


Financial performance View All

Revenue Cost of Revenue Gross Profit Net Income ebitda EPS
Q3 '2452M22M29M940,000-3.3M0.010
Q2 '2447M21M25M-10M-7.6M-0.080
Q1 '2445M22M23M-6.2M-7.7M-0.050
Q4 '2358M25M33M5.5M5.4M0.040
Q3 '2348M21M27M-6.5M-2.7M-0.050

Insider Transactions View All

Yan Ming filed to sell 5,988,502 shares at $5.9.
April 23 '24
Yan Ming filed to sell 6,008,502 shares at $7.
April 11 '24
Yan Ming filed to sell 6,008,902 shares at $7.
April 11 '24
Yan Ming filed to sell 6,010,402 shares at $6.7.
March 19 '24
Jeanmonod Patrik filed to sell 93,400 shares at $9.5.
December 27 '23

What is the Market Cap of Cytek BioSciences?

The Market Cap of Cytek BioSciences is $862M.

What is Cytek BioSciences' PE Ratio?

As of today, Cytek BioSciences' PE (Price to Earnings) ratio is 351.5.

What is the current stock price of Cytek BioSciences?

Currently, the price of one share of Cytek BioSciences stock is $6.50.

How can I analyze the CTKB stock price chart for investment decisions?

The CTKB stock price chart above provides a comprehensive visual representation of Cytek BioSciences' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Cytek BioSciences shares. Our platform offers an up-to-date CTKB stock price chart, along with technical data analysis and alternative data insights.

Does CTKB offer dividends to its shareholders?

As of our latest update, Cytek BioSciences (CTKB) does not offer dividends to its shareholders. Investors interested in Cytek BioSciences should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.

What are some of the similar stocks of Cytek BioSciences?

Some of the similar stocks of Cytek BioSciences are Boston Scientific, Edwards Lifesciences, Intuitive Surgical, Medtronic, and Stryker.

.
The analytics provided are estimates and not a substitute for professional advice. All investments involve risks, including possible capital loss.
About Us

AltIndex revolutionizes investing with advanced alternative data analytics, smart insights, and stock alerts, presented in an easy-to-use dashboard powered by comprehensive company data from across the internet.



App download

Legal Disclaimer
The information provided by AltIndex is solely for informational purposes and not a substitute for professional financial advice. Investing in financial markets carries inherent risks, and past performance doesn't guarantee future results. It's crucial to do your research, consult with financial experts, and align your financial objectives and risk tolerance before investing. AltIndex creators and operators are not liable for any financial losses incurred from using this information. Users should exercise caution, seek professional advice, and be prepared for the risks involved in trading and investing in financial assets, only investing what they can afford to lose. The information in this application, derived from publicly available data, is believed to be reliable but may not always be accurate or current. Users should verify information independently and not solely rely on this application for financial decisions. By using AltIndex, you acknowledge that it doesn't offer financial advice and agree to consult a qualified financial advisor before making investment decisions.

© 2024 AltIndex. All rights reserved.